The effectiveness of quality control samples in pharmaceutical bioanalysis.

QC failure QCs bioanalysis bioanalytical data quality failed runs quality controls repeat runs sample retesting

Journal

Bioanalysis
ISSN: 1757-6199
Titre abrégé: Bioanalysis
Pays: England
ID NLM: 101512484

Informations de publication

Date de publication:
Feb 2021
Historique:
pubmed: 5 2 2021
medline: 1 9 2021
entrez: 4 2 2021
Statut: ppublish

Résumé

The use of quality control (QC) samples in bioanalysis is well established and consistent with regulatory guidance. However, a systematic evaluation of whether QC samples serve the intended purpose of improving data quality has not been undertaken. The Translational and ADME Sciences Leadership Group (TALG) of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) conducted an evaluation to assess whether closer agreement is observed when comparing pharmacokinetic data from two passed runs, than when comparing data from failed and passed (retest) runs. Analysis of data collected across organizations, molecular types and analytical platforms, revealed that bioanalytical methods are very reproducible; and that QC samples improve the overall quality of pharmacokinetic concentration data and justifies their continued use.

Identifiants

pubmed: 33538614
doi: 10.4155/bio-2020-0265
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-145

Auteurs

Stephen Keller (S)

AbbVie, Inc., Redwood City, CA 94063, USA.

Jorge Quiroz (J)

Merck & Co Inc., Kenilworth, NJ 07033, USA.

Dave Christopher (D)

Merck & Co., West Point, PA 19486, USA.

Enaksha Wickremsinhe (E)

Eli Lilly & Company, Indianapolis, IN 46225, USA.

Wanping Geng (W)

EMD Serono, Billerica, MA 01821, USA.

Glen Hawthorne (G)

AstraZeneca, Cambridge, UK.

Christopher James (C)

Amgen Research, Thousand Oaks, CA 91320, USA.

Yvonne Katterle (Y)

Bayer Pharma AG, Berlin, Germany.

Wenkui Li (W)

Novartis Institutes for BioMedical Research, East Hanover, NJ 07936, USA.

Guowen Liu (G)

Agios Pharmaceuticals, Cambridge, MA 02139, USA.

Andrew Mayer (A)

GlaxoSmithKline, Collegeville, PA 19426, USA.

Martin Paton (M)

Takeda Pharmaceuticals International Co, Cambridge, MA 02139, USA.

Joseph Pav (J)

Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA.

Julian Potter (J)

F. Hoffmann-La Roche Ltd., Basel, Switzerland.

James Vergis (J)

Faegre Drinker Biddle & Reath LLP, Washington, DC 20001, USA.

Jonathan Wang (J)

Genentech, Inc. Genentech Inc., South San Francisco, CA 94080, USA.

Lucas Westcott-Baker (L)

Otsuka Pharmaceutical, Rockville, MD 20850, USA.

Eric Woolf (E)

Merck & Co., West Point, PA 19486, USA.

Yongjun Xue (Y)

Bristol-Myers Squibb Co. Princeton, NJ 08540, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH